Sung-Hoo Hong Selected Research

lenvatinib

1/2024	Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
1/2023	Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
1/2023	Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
1/2023	Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
1/2022	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
1/2021	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sung-Hoo Hong Research Topics

Disease

33	Renal Cell Carcinoma (Grawitz Tumor) 03/2024 - 03/2013
16	Neoplasms (Cancer) 03/2024 - 08/2014
16	Prostatic Neoplasms (Prostate Cancer) 02/2024 - 01/2012
11	Erectile Dysfunction 06/2021 - 10/2012
10	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2017
5	Hypertension (High Blood Pressure) 01/2023 - 12/2013
5	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 03/2016 - 04/2011
4	Chronic Renal Insufficiency 03/2024 - 12/2013
4	Pelvic Pain 02/2024 - 01/2019
4	Prostatitis 02/2024 - 08/2018
4	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 10/2005
4	Diabetes Mellitus 06/2021 - 11/2018
3	Inflammation (Inflammations) 02/2024 - 08/2018
3	Kidney Neoplasms (Kidney Cancer) 01/2024 - 01/2021
3	Carcinoma (Carcinomatosis) 09/2023 - 10/2020
3	Hyperplasia 04/2020 - 08/2014
2	Necrosis 01/2024 - 01/2017
2	Body Weight (Weight, Body) 07/2023 - 01/2014
2	Margins of Excision 01/2022 - 07/2016
2	Ganglion Cysts (Ganglion) 01/2021 - 10/2012
2	Disease Progression 01/2021 - 10/2020
2	Postoperative Pain 04/2018 - 12/2014
2	Cicatrix (Scar) 08/2015 - 07/2006
1	Flank Pain 04/2024
1	Hyperthermia 02/2024
1	Hand-Foot Syndrome 01/2023
1	Drug-Related Side Effects and Adverse Reactions 01/2023
1	Hyperhidrosis 11/2021
1	Diarrhea 01/2021
1	Neurogenic Urinary Bladder (Bladder, Neurogenic) 01/2021
1	Ototoxicity 10/2020
1	Urinary Incontinence 04/2020
1	Overactive Urinary Bladder (Overactive Bladder) 04/2020
1	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction) 04/2020

Drug/Important Bio-Agent (IBA)

7	Sunitinib (Sutent)FDA Link 01/2024 - 12/2018
6	lenvatinibIBA 01/2024 - 01/2021
6	pembrolizumabIBA 01/2024 - 01/2021
5	CholesterolIBA 07/2023 - 01/2017
5	Prostate-Specific Antigen (Semenogelase)IBA 03/2023 - 01/2012
3	Hemoglobins (Hemoglobin)IBA 08/2021 - 01/2020
3	CalciumIBA 08/2021 - 12/2013
3	Streptozocin (Streptozotocin)FDA Link 06/2021 - 07/2016
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2012
3	Serum AlbuminIBA 01/2020 - 12/2013
3	CreatinineIBA 04/2014 - 05/2013
2	AlbuminsIBA 03/2024 - 01/2020
2	HMGB1 Protein (HMG1)IBA 02/2024 - 01/2021
2	AndrogensIBA 01/2024 - 07/2023
2	Hormones (Hormone)IBA 01/2024 - 03/2019
2	abirateroneIBA 01/2024 - 01/2023
2	Everolimus FDA Link 01/2022 - 01/2021
2	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2014
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021 - 10/2012
2	PlatinumIBA 01/2021 - 10/2020
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 11/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 05/2018 - 01/2018
2	Sorafenib (BAY 43-9006)FDA Link 01/2017 - 01/2015
2	Analgesics (Analgesic Drugs)IBA 08/2015 - 05/2013
1	bicalutamide (Casodex)FDA LinkGeneric 02/2024
1	Toll-Like Receptor 4IBA 02/2024
1	CytokinesIBA 02/2024
1	Prednisone (Sone)FDA LinkGeneric 01/2024
1	Triglycerides (Triacylglycerol)IBA 07/2023
1	LDL CholesterolIBA 07/2023
1	Testosterone (Sustanon)FDA Link 07/2023
1	HDL CholesterolIBA 07/2023
1	AntigensIBA 03/2023
1	Prednisolone (Predate)FDA LinkGeneric 01/2023
1	antiarrhythmic peptide (AAP)IBA 01/2023
1	Abiraterone AcetateIBA 01/2023
1	Roundabout ProteinsIBA 10/2021
1	Alkaline PhosphataseIBA 08/2021
1	Niclosamide FDA Link 01/2021
1	Type I Tumor Necrosis Factor ReceptorsIBA 01/2021
1	Lipase (Acid Lipase)FDA Link 01/2021
1	Gemcitabine FDA Link 10/2020
1	DA-8010IBA 04/2020
1	salicylhydroxamic acid (SHAM)IBA 04/2020
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 04/2020

Therapy/Procedure

21	Nephrectomy 03/2024 - 03/2013
17	Therapeutics 01/2024 - 01/2015
6	Extracorporeal Shockwave Therapy 10/2022 - 01/2019
6	Prostatectomy (Retropubic Prostatectomy) 10/2021 - 07/2006
5	Castration 02/2024 - 01/2019
5	Lasers (Laser) 04/2020 - 04/2011
3	Drug Therapy (Chemotherapy) 01/2023 - 10/2020
3	Blood Transfusion (Blood Transfusions) 01/2022 - 01/2016
3	Percutaneous Nephrolithotomy 04/2018 - 08/2012
3	Cystectomy 01/2010 - 10/2005
2	Stents 04/2024 - 08/2014
2	Aftercare (After-Treatment) 07/2023 - 03/2013
2	Duration of Therapy 12/2022 - 01/2015
2	Metastasectomy 01/2021 - 01/2019
2	Length of Stay 03/2019 - 12/2014
2	Nephrotomy 04/2018 - 11/2011
1	Nephroureterectomy 09/2023
1	Sympathectomy (Sympathectomies) 11/2021
1	Anesthesia 01/2021
1	Oral Administration 04/2020